The availability and use of intravenous lipid-based drug products is increasing. These products may have increased efficacy, decreased adverse effects, or both when compared with conventional formulations of the same drug. Lipid-based drug products have nutrition support implications when a substantial caloric dose is received during administration of the drug. They also may have unique toxicities and much greater costs than do traditional therapies. The rationale for the use of lipid-based drug products is presented, along with an overview of the proper use of current commercially available lipid-based amphotericin B, propofol, daunonubicin, and doxorubicin products.